<DOC>
	<DOCNO>NCT01232556</DOCNO>
	<brief_summary>The purpose study evaluate efficacy inotuzumab ozogamicin plus rituximab relapsed/refractory aggressive Non-Hodgkin lymphoma patient candidate intensive high-dose chemotherapy . Specifically , goal demonstrate superiority combination compare active comparator arm ( investigator 's choice rituximab+bendamustine rituximab+gemcitabine ) use primary endpoint overall survival .</brief_summary>
	<brief_title>A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>relapsed/refractory/persistent CD20+/CD22+ aggressive NHL ( DLBCL , transform indolent lymphoma DLBCL , primary mediastinal large Bcell lymphoma ) 3 prior regimen contain cytotoxic chemotherapy candidate intensive highdose chemotherapy , without autologous stem cell transplant Any prior allogeneic hematopoietic stem cell transplant ; autotransplant within prior 4 month antiCD22 treatment radioimmunotherapy within prior 6 month contraindication investigator choice regimens chronic liver disease , history venoocclusive disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>inotuzumab ozogamicin</keyword>
	<keyword>aggressive Non-Hodgkin lymphoma</keyword>
	<keyword>diffuse large b-cell lymphoma</keyword>
	<keyword>relapsed/refractory lymphoma</keyword>
</DOC>